메뉴 건너뛰기
Multiple Sclerosis Journal
Volumn 18, Issue 12, 2012, Pages 1680-1681
The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Yes
Author keywords

[No Author keywords available]
Indexed keywords

NEUROPROTECTIVE AGENT;
EID: 84871583571     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512464687     Document Type: Note
Times cited : (2)
References (11)
  • 1
    • 77950244111 scopus 로고    scopus 로고
    • Primary neuroprotection: The Holy Grail of multiple sclerosis therapy
    • Fox RJ. Primary neuroprotection: The Holy Grail of multiple sclerosis therapy. Neurology. 2010 ; 74: 1018-1019
    • (2010) Neurology , vol.74 , pp. 1018-1019
    • Fox, R.J.1
  • 2
    • 77954686670 scopus 로고    scopus 로고
    • Clinico- pathological evidence that axonal loss underlies disability in progressive multiple sclerosis
    • Tallantyre EC, Bø L, Al-Rawashdeh O, et al. Clinico- pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler. 2010 ; 16: 406-411
    • (2010) Mult Scler , vol.16 , pp. 406-411
    • Tallantyre, E.C.1    Bø, L.2    Al-Rawashdeh, O.3
  • 3
    • 0032576752 scopus 로고    scopus 로고
    • Axonal transection in the lesions of multiple sclerosis
    • Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285
    • (1998) N Engl J Med , vol.338 , pp. 278-285
    • Trapp, B.D.1    Peterson, J.2    Ransohoff, R.M.3
  • 4
    • 66549130329 scopus 로고    scopus 로고
    • The relation between inflammation and neurodegeneration in multiple sclerosis brains
    • Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 ; 132: 1175-1189
    • (2009) Brain , vol.132 , pp. 1175-1189
    • Frischer, J.M.1    Bramow, S.2    Dal-Bianco, A.3
  • 5
    • 63849213783 scopus 로고    scopus 로고
    • Inflammation triggers synaptic alteration and degeneration in experimental auto-immune encephalomyelitis
    • Centonze D, Muzio L, Rossi S, et al. Inflammation triggers synaptic alteration and degeneration in experimental auto-immune encephalomyelitis. J Neurosci. 2009 ; 29: 3442-3452
    • (2009) J Neurosci , vol.29 , pp. 3442-3452
    • Centonze, D.1    Muzio, L.2    Rossi, S.3
  • 6
    • 79954424929 scopus 로고    scopus 로고
    • Spinal cord histo-pathology of MOG peptide 35-55-induced experimental autoimmune encephalomyelitis is time- and score-dependent
    • Recks MS, Addicks K, Kuerten S. Spinal cord histo-pathology of MOG peptide 35-55-induced experimental autoimmune encephalomyelitis is time- and score-dependent. Neurosci Lett. 2011 ; 494: 227-231
    • (2011) Neurosci Lett , vol.494 , pp. 227-231
    • Recks, M.S.1    Addicks, K.2    Kuerten, S.3
  • 7
    • 79960258821 scopus 로고    scopus 로고
    • Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis
    • Al-Izki S, Pryce G, Jackson SJ, et al. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler. 2011 ; 17: 939-948
    • (2011) Mult Scler , vol.17 , pp. 939-948
    • Al-Izki, S.1    Pryce, G.2    Jackson, S.J.3
  • 8
    • 39749200152 scopus 로고    scopus 로고
    • Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis
    • Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 ; 131 (Pt 3). 808-817
    • (2008) Brain , vol.131 , Issue.PART 3 , pp. 808-817
    • Fisniku, L.K.1    Brex, P.A.2    Altmann, D.R.3
  • 9
    • 35148881670 scopus 로고    scopus 로고
    • How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    • Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. Neurology. 2007 ; 69: 1498-1507
    • (2007) Neurology , vol.69 , pp. 1498-1507
    • Brown, M.G.1    Kirby, S.2    Skedgel, C.3
  • 10
    • 54949143968 scopus 로고    scopus 로고
    • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
    • Coles AJ, Compston DAS, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 ; 359: 1786-1801
    • (2008) N Engl J Med , vol.359 , pp. 1786-1801
    • Coles, A.J.1    Das, C.2    Selmaj, K.W.3
  • 11
    • 84867707040 scopus 로고    scopus 로고
    • Meningeal in-flammation plays a role in the pathology of primary progressive multiple sclerosis
    • ChoiSRHowellOWCarassitiD. Meningeal in-flammation plays a role in the pathology of primary progressive multiple sclerosis. Brain2012; 135 (pt 10): 2925-2937.
    • Brain2012 , vol.135 , Issue.PART 10 , pp. 2925-2937
    • Choi, S.R.1    Howell, O.W.2    Carassiti, D.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.